Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Ceribelli M, Tosto FA, Zhang X, Melani CJ, Roschewski M, Beck E, Klumpp-Thomas C, Peer CJ, Wilson KM, Chen L, McKnight C, Michael S, Itkin Z, Shinn P, Figg WD Sr, Wilson WH, Staudt LM, Thomas CJ. Ceribelli M, et al. Among authors: roschewski m. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2413372121. doi: 10.1073/pnas.2413372121. Epub 2024 Nov 25. Proc Natl Acad Sci U S A. 2024. PMID: 39585996 Free PMC article.
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Maakaron JE, Asch A, Popplewell L, Collins GP, Flinn IW, Ghosh N, Keane C, Ku M, Mehta A, Roschewski M, Hacohen-Kleiman G, Huo Y, Zhang Y, Renard C, Smith SM, Advani R. Maakaron JE, et al. Among authors: roschewski m. Blood Adv. 2024 Nov 26;8(22):5864-5874. doi: 10.1182/bloodadvances.2024013338. Blood Adv. 2024. PMID: 39293083 Free PMC article. Clinical Trial.
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.
Mehta A, Popplewell L, Collins GP, Smith SM, Flinn IW, Bartlett NL, Ghosh N, Hacohen-Kleiman G, Huo Y, Su-Feher L, Renard C, Advani R, Roschewski M. Mehta A, et al. Among authors: roschewski m. Blood Adv. 2024 Nov 26;8(22):5855-5863. doi: 10.1182/bloodadvances.2024013277. Blood Adv. 2024. PMID: 39213421 Free PMC article. Clinical Trial.
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, Simard J, Muppidi J, Thomas CJ, Ceribelli M, Tosto FA, Yang Y, Xu W, Davies-Hill T, Pack SD, Peer CJ, Arisa O, Mena E, Lindenberg L, Bergvall E, Portell CA, Farah RJ, Lee ST, Pradhan A, Morrison C, Tadese A, Juanitez AM, Lu C, Jacob A, Simmons H, Figg WD, Steinberg SM, Jaffe ES, Roschewski M, Staudt LM, Wilson WH. Melani C, et al. Among authors: roschewski m. N Engl J Med. 2024 Jun 20;390(23):2143-2155. doi: 10.1056/NEJMoa2401532. N Engl J Med. 2024. PMID: 38899693 Free PMC article. Clinical Trial.
BTK drives neutrophil activation for sterilizing antifungal immunity.
Desai JV, Zarakas MA, Wishart AL, Roschewski M, Aufiero MA, Donkó Á, Wigerblad G, Shlezinger N, Plate M, James MR, Lim JK, Uzel G, Bergerson JR, Fuss I, Cramer RA, Franco LM, Clark ES, Khan WN, Yamanaka D, Chamilos G, El-Benna J, Kaplan MJ, Staudt LM, Leto TL, Holland SM, Wilson WH, Hohl TM, Lionakis MS. Desai JV, et al. Among authors: roschewski m. J Clin Invest. 2024 May 2;134(12):e176142. doi: 10.1172/JCI176142. Online ahead of print. J Clin Invest. 2024. PMID: 38696257 Free PMC article.
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.
Radtke AJ, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, Meerson M, Polyakova M, Galkin I, Svekolkin V, Isaev S, Wiebe D, Sharun A, Sarachakov A, Perelman G, Lozinsky Y, Yaniv Z, Lowekamp BC, Speranza E, Yao L, Pittaluga S, Shaffer AL 3rd, Jonigk D, Phelan JD, Davies-Hill T, Huang DW, Ovcharov P, Nomie K, Nuzhdina E, Kotlov N, Ataullakhanov R, Fowler N, Kelly M, Muppidi J, Davis JL, Hernandez JM, Wilson WH, Jaffe ES, Staudt LM, Roschewski M, Germain RN. Radtke AJ, et al. Among authors: roschewski m. Cancer Cell. 2024 Mar 11;42(3):444-463.e10. doi: 10.1016/j.ccell.2024.02.001. Epub 2024 Feb 29. Cancer Cell. 2024. PMID: 38428410
Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.
Shukla ND, Schroers-Martin JG, Sworder BJ, Kathuria KR, Alig SK, Frank MJ, Miklos DB, Coutre S, Diehn M, Khodadoust MS, Roschewski M, Kurtz DM, Alizadeh AA. Shukla ND, et al. Among authors: roschewski m. Blood Adv. 2024 Feb 13;8(3):780-784. doi: 10.1182/bloodadvances.2023011997. Blood Adv. 2024. PMID: 38147627 Free PMC article. No abstract available.
119 results